At the news
? BULLISHIMPACT 7/10 8-K filed Jun 1, 2026 at 09:15 ET
Outlook Therapeutics resubmitted its Biologics License Application (BLA) for ONS-5010/LYTENAVA (bevacizumab-vikg) to the FDA for the treatment of neovascular age-related macular degeneration (nAMD). The FDA Office of New Drugs previously concluded that substantial evidence of effectiveness has been established, and this is a Class 1 resubmission with a PDUFA decision expected within 60 days.
- BLA resubmitted to FDA on June 1, 2026 for ONS-5010/LYTENAVA (bevacizumab-vikg) for nAMD.
- FDA Office of New Drugs concluded substantial evidence of effectiveness has been established; no additional trials required.
- Class 1 resubmission with PDUFA decision expected within 60 days of FDA receipt.
- Product already has Marketing Authorization in the EU and UK; commercial launch commenced in Germany, Austria, and the UK.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access